Pruritus Pipeline Insight
DelveInsight’s, “Pruritus - Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Pruritus pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Pruritus, also known as itching is defined as an unpleasant sensation that provokes the desire to scratch. Beyond an itching sensation, symptoms of pruritus can include redness, blisters, dry, cracked and scaly skin. Itch has been categorized into the following four classifications: cutaneous, neuropathic, neurogenic, and psychogenic. Pruritus, or itch, is most commonly associated with a primary skin disorder such as xerosis, atopic dermatitis, drug eruption, urticaria, psoriasis, arthropod assault, mastocytosis, dermatitis herpetiformis, or pemphigoid. Diagnostic testing is directed by the clinical evaluation and may include a complete blood count and measurement of thyroid-stimulating hormone, serum bilirubin, alkaline phosphatase, serum creatinine, and blood urea nitrogen levels. The treatment of pruritus includes topical agents, systemic agents, physical modalities, and non-pharmacological treatments.
"Pruritus - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pruritus pipeline landscape is provided which includes the disease overview and Pruritus treatment guidelines. The assessment part of the report embraces, in depth Pruritus commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pruritus collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Pruritus R&D. The therapies under development are focused on novel approaches to treat/improve Pruritus.
Pruritus Emerging Drugs Chapters
This segment of the Pruritus report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Pruritus Emerging Drugs
Difelikefalin: Cara Therapeutics
Difelikefalin is a small peptide molecule based peripheral kappa opioid receptor agonist. In March 2021, FDA has accepted for priority review the New Drug Application (NDA) for difelikefalin (Korsuva), for the treatment of moderate to severe pruritus in hemodialysis patients. The PDUFA target action date for KORSUVA is 23 August 2021. The drug is also in clinical studies for the management of pain and renal failure.
BLU-5937: BELLUS Health
BLU-5937 is an orally available small molecule based P2X3 antagonist. The drug is in Phase II clinical developmental studies for the treatment of chronic cough and chronic pruritus.
Further product details are provided in the report……..
Pruritus: Therapeutic Assessment
This segment of the report provides insights about the different Pruritus drugs segregated based on following parameters that define the scope of the report, such as:
- • Major Players in Pruritus
There are approx. 40+ key companies which are developing the therapies for Pruritus. The companies which have their Pruritus drug candidates in the most advanced stage, i.e. Preregistration include, Cara Therapeutics.
DelveInsight’s report covers around 40+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Pruritus pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Pruritus: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Pruritus therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pruritus drugs.
Pruritus Report Insights
- Pruritus Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Pruritus Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Pruritus drugs?
- How many Pruritus drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pruritus?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pruritus therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Pruritus and their status?
- What are the key designations that have been granted to the emerging drugs?